Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01639391

Acronym

ALSCELL

Enrollment

Registered

2012-07-12

Start date

2012-11-29

Completion date

2015-03-17

Last updated

2018-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Brief summary

Patients with ALS will be included in the reference center for ALS in hospital La Pitié Salpêtrière, Paris. The study proposes to investigate the pathophysiology of ALS by setting up a fibroblast bank for studying molecular, cellular and genetic parameters of the pathology. iPS (induced pluripotent stem cells) and then differentiated cells will be generated. The pathophysiology of ALS will be studied on the 3 types of cells (fibroblasts, iPS, differentiated cells).

Interventions

PROCEDUREskin biopsy

biopsy 5mm maximum on healthy skin under local anaesthesia.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients over 18 years old * ALS sporadic or familial or unknown

Exclusion criteria

* known cutaneous disease not allowing the biopsy * platelets less than 10 000/m3 * suspected or known xylocain allergy

Design outcomes

Primary

Measure	Time frame
Success of fibroblast culture, amplification, and freezing pellets	2 months

Secondary

Measure	Time frame
Induced pluripotent Stem Cells generation success	2 years
neurones, motoneurones, glial cells obtention from fibroblasts or iPS	2 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026